The Effects of Sleeve Gastrectomy on Fractalkine

NCT07655739 | Completed

• 1 other identifier: 2025/14-21
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Fractalkine (CX3CL1) is a unique chemokine involved in leukocyte adhesion, migration, and obesity-associated adipose tissue inflammation. Although bariatric surgery results in substantial weight loss and metabolic improvement, the temporal pattern of circulating CX3CL1 levels following laparoscopic sleeve gastrectomy (LSG) remains poorly understood. This study aimed to evaluate longitudinal changes in serum CX3CL1 levels after LSG and to investigate their association with postoperative weight loss.

Conditions

Obesity & Overweight

Keywords

Fractalkine; CX3CL1; Sleeve gastrectomy; Morbid obesity; Weight loss; Inflammation

Outcome Measures

Primary Outcomes (2)

• Fractalcine levels changes after laparoscopic sleeve gastrectomy

  Fractalcine levels changes between preoperative and postop operative third month

  3 months

• Weight lost levels after obesity surgery

  Preoperative and the postoperative third month's Total weight lost percentage and excess weight loss percentage were calculated.

  3 months

Study Arms (1)

Obesity Surgery Patients undergoing Laparoscopic Sleeve Gastrectomy

Obesity Surgery Patients undergoing Laparoscopic Sleeve Gastrectomy

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with a body mass index (BMI) ≥40 kg/m² or a BMI ≥35 kg/m² in the presence of at least one obesity-related comorbidity who were planned for Laparoscopic Sleeve Gastrectomy.

You may qualify if:

• Age ≥18 years
• Elective laparoscopic sleeve gastrectomy
• Provision of written informed consent for study participation and scheduled follow-up assessments

You may not qualify if:

• Active infection or acute inflammatory condition
• Autoimmune or chronic inflammatory disease
• History of malignancy
• Chronic liver or kidney disease
• Pregnancy or lactation
• Corticosteroid or immunosuppressive therapy
• Major postoperative complications
• Missing data or incomplete sampling

Sponsors & Collaborators

• Mehmet Buğra Bozan: lead

Study Sites (1)

Elazig Fethi Sekin City Hospital

Elâzığ, 23100, Turkey (Türkiye)

Location

Related Publications (17)

• Polyak A, Ferenczi S, Denes A, Winkler Z, Kriszt R, Pinter-Kubler B, Kovacs KJ. The fractalkine/Cx3CR1 system is implicated in the development of metabolic visceral adipose tissue inflammation in obesity. Brain Behav Immun. 2014 May;38:25-35. doi: 10.1016/j.bbi.2014.01.010. Epub 2014 Jan 21.

  PMID: 24456845 BACKGROUND

• Swalsingh G, Pani P, Sadayappan S, Bal NC. Fractalkine is a key player in skeletal muscle metabolism and pathophysiology. FEBS J. 2026 Apr;293(7):1865-1881. doi: 10.1111/febs.70267. Epub 2025 Sep 25.

  PMID: 40995677 BACKGROUND

• Sirois-Gagnon D, Chamberland A, Perron S, Brisson D, Gaudet D, Laprise C. Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obesity (Silver Spring). 2011 Jan;19(1):222-7. doi: 10.1038/oby.2010.125. Epub 2010 Jun 3.

  PMID: 20523302 BACKGROUND

• Cefalu WT. Fractalkine: a cellular link between adipose tissue inflammation and vascular pathologies. Diabetes. 2011 May;60(5):1380-2. doi: 10.2337/db11-0239. No abstract available.

  PMID: 21525509 BACKGROUND

• Morris DL, Oatmen KE, Wang T, DelProposto JL, Lumeng CN. CX3CR1 deficiency does not influence trafficking of adipose tissue macrophages in mice with diet-induced obesity. Obesity (Silver Spring). 2012 Jun;20(6):1189-99. doi: 10.1038/oby.2012.7. Epub 2012 Jan 17.

  PMID: 22252034 BACKGROUND

• Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, Lu Y, Putt ME, Ahima RS, Reilly MP. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011 May;60(5):1512-8. doi: 10.2337/db10-0956.

  PMID: 21525510 BACKGROUND

• Rivera-Carranza T, Azaola-Espinosa A, Bojalil-Parra R, Zuniga-Leon E, Leon-Tellez-Giron A, Rojano-Rodriguez ME, Najera-Medina O. Immunometabolic Changes Following Gastric Bypass and Sleeve Gastrectomy: A Comparative Study. Obes Surg. 2025 Feb;35(2):481-495. doi: 10.1007/s11695-024-07598-3. Epub 2025 Jan 11.

  PMID: 39794663 BACKGROUND

• Subramaniam R, Aliakbarian H, Bhutta HY, Harris DA, Tavakkoli A, Sheu EG. Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Attenuate Pro-inflammatory Small Intestinal Cytokine Signatures. Obes Surg. 2019 Dec;29(12):3824-3832. doi: 10.1007/s11695-019-04059-0.

  PMID: 31363962 BACKGROUND

• Farsad F, Salimpour S, Mirhashemi S, Jolfaei P, Erfanifar A, Toreyhi H, Davoudi Z. Impact of BMI Reduction After Sleeve Surgery on ESR and CRP Levels in Patients with Obesity. Obes Surg. 2025 Apr;35(4):1307-1315. doi: 10.1007/s11695-025-07746-3. Epub 2025 Mar 3.

  PMID: 40025344 BACKGROUND

• Surve A, Cottam D, Pryor A, Cottam S, Michaelson R, Umbach T, Williams M, Bagshahi H, July L, Bueno R, Chock D, Apel M, Hart C, Johnson W, Curtis B, Rosenbluth A, Spaniolas K, Medlin W, Wright W, Lee C, Lee C, Trujeque R, Rinker D. A Prospective Multicenter Standard of Care Study of Outpatient Laparoscopic Sleeve Gastrectomy. Obes Surg. 2024 Apr;34(4):1122-1130. doi: 10.1007/s11695-024-07094-8. Epub 2024 Feb 17.

  PMID: 38366263 BACKGROUND

• Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022 Jan 11;55(1):31-55. doi: 10.1016/j.immuni.2021.12.013.

  PMID: 35021057 BACKGROUND

• Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, Beguinot F. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2020 Jan 29;10:1607. doi: 10.3389/fphys.2019.01607. eCollection 2019.

  PMID: 32063863 BACKGROUND

• Crasan IM, Tanase M, Delia CE, Gradisteanu-Pircalabioru G, Cimpean A, Ionica E. Metaflammation's Role in Systemic Dysfunction in Obesity: A Comprehensive Review. Int J Mol Sci. 2025 Oct 27;26(21):10445. doi: 10.3390/ijms262110445.

  PMID: 41226484 BACKGROUND

• Engin A. Reappraisal of Adipose Tissue Inflammation in Obesity. Adv Exp Med Biol. 2024;1460:297-327. doi: 10.1007/978-3-031-63657-8_10.

  PMID: 39287856 BACKGROUND

• Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021 May;137:111315. doi: 10.1016/j.biopha.2021.111315. Epub 2021 Feb 6.

  PMID: 33561645 BACKGROUND

• Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. Cancers (Basel). 2023 Jan 12;15(2):485. doi: 10.3390/cancers15020485.

  PMID: 36672434 BACKGROUND

• Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017 Jan 3;127(1):1-4. doi: 10.1172/JCI92035. Epub 2017 Jan 3.

  PMID: 28045402 BACKGROUND

MeSH Terms

Conditions

Obesity; Overweight; Obesity, Morbid; Weight Loss; Inflammation

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Body Weight Changes; Pathologic Processes

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor, Associate

Study Record Dates

• First Submitted: June 13, 2026
• First Posted: June 18, 2026
• Study Start: September 4, 2025
• Primary Completion: January 4, 2026
• Study Completion: February 4, 2026
• Last Updated: June 18, 2026

Record last verified: 2026-06

Locations

TU (1)